Engineered proteolytic nanobodies reduce Aβ burden and ameliorate Aβ-induced cytotoxicity

Srinath Kasturirangan, Shanta Boddapati, Michael Sierks

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Deposition of β-amyloid (Aβ) is considered an important early event in the pathogenesis of Alzheimer's disease (AD), and reduction of Aβ levels in the brain could be a viable therapeutic approach. A potentially noninflammatory route to facilitate clearance and reduce toxicity of Aβ is to degrade the peptide using proteolytic nanobodies. Here we show that a proteolytic nanobody engineered to cleave Aβ at its α-secretase site has potential therapeutic value. The Asec-1A proteolytic nanobody, derived from a parent catalytic light chain antibody, prevents aggregation of monomeric Aβ, inhibits further aggregation of preformed Aβ aggregates, and reduces Aβ-induced cytotoxicity toward a human neuroblastoma cell line. The nanobody also reduces toxicity induced by overexpression of the human amyloid precursor protein (APP) in a Chinese hamster ovary (CHO) cell line by cleaving APP at the α-secretase site which precludes formation of Aβ. Targeted proteolysis of APP and Aβ with catalytic nanobodies represents a novel therapeutic approach for treating AD where potentially harmful side effects can be minimized.

Original languageEnglish (US)
Pages (from-to)4501-4508
Number of pages8
JournalBiochemistry
Volume49
Issue number21
DOIs
StatePublished - Jun 1 2010

Fingerprint

Single-Domain Antibodies
Cytotoxicity
Serum Amyloid A Protein
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Toxicity
Alzheimer Disease
Agglomeration
Cells
Proteolysis
Cell Line
Staphylococcal Protein A
Cricetulus
Neuroblastoma
Amyloid
Ovary
Brain
Therapeutics
Light
Peptides

ASJC Scopus subject areas

  • Biochemistry

Cite this

Engineered proteolytic nanobodies reduce Aβ burden and ameliorate Aβ-induced cytotoxicity. / Kasturirangan, Srinath; Boddapati, Shanta; Sierks, Michael.

In: Biochemistry, Vol. 49, No. 21, 01.06.2010, p. 4501-4508.

Research output: Contribution to journalArticle

Kasturirangan, Srinath ; Boddapati, Shanta ; Sierks, Michael. / Engineered proteolytic nanobodies reduce Aβ burden and ameliorate Aβ-induced cytotoxicity. In: Biochemistry. 2010 ; Vol. 49, No. 21. pp. 4501-4508.
@article{2af88de5ce1248cebd3bc4f5c8eb1b88,
title = "Engineered proteolytic nanobodies reduce Aβ burden and ameliorate Aβ-induced cytotoxicity",
abstract = "Deposition of β-amyloid (Aβ) is considered an important early event in the pathogenesis of Alzheimer's disease (AD), and reduction of Aβ levels in the brain could be a viable therapeutic approach. A potentially noninflammatory route to facilitate clearance and reduce toxicity of Aβ is to degrade the peptide using proteolytic nanobodies. Here we show that a proteolytic nanobody engineered to cleave Aβ at its α-secretase site has potential therapeutic value. The Asec-1A proteolytic nanobody, derived from a parent catalytic light chain antibody, prevents aggregation of monomeric Aβ, inhibits further aggregation of preformed Aβ aggregates, and reduces Aβ-induced cytotoxicity toward a human neuroblastoma cell line. The nanobody also reduces toxicity induced by overexpression of the human amyloid precursor protein (APP) in a Chinese hamster ovary (CHO) cell line by cleaving APP at the α-secretase site which precludes formation of Aβ. Targeted proteolysis of APP and Aβ with catalytic nanobodies represents a novel therapeutic approach for treating AD where potentially harmful side effects can be minimized.",
author = "Srinath Kasturirangan and Shanta Boddapati and Michael Sierks",
year = "2010",
month = "6",
day = "1",
doi = "10.1021/bi902030m",
language = "English (US)",
volume = "49",
pages = "4501--4508",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "21",

}

TY - JOUR

T1 - Engineered proteolytic nanobodies reduce Aβ burden and ameliorate Aβ-induced cytotoxicity

AU - Kasturirangan, Srinath

AU - Boddapati, Shanta

AU - Sierks, Michael

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Deposition of β-amyloid (Aβ) is considered an important early event in the pathogenesis of Alzheimer's disease (AD), and reduction of Aβ levels in the brain could be a viable therapeutic approach. A potentially noninflammatory route to facilitate clearance and reduce toxicity of Aβ is to degrade the peptide using proteolytic nanobodies. Here we show that a proteolytic nanobody engineered to cleave Aβ at its α-secretase site has potential therapeutic value. The Asec-1A proteolytic nanobody, derived from a parent catalytic light chain antibody, prevents aggregation of monomeric Aβ, inhibits further aggregation of preformed Aβ aggregates, and reduces Aβ-induced cytotoxicity toward a human neuroblastoma cell line. The nanobody also reduces toxicity induced by overexpression of the human amyloid precursor protein (APP) in a Chinese hamster ovary (CHO) cell line by cleaving APP at the α-secretase site which precludes formation of Aβ. Targeted proteolysis of APP and Aβ with catalytic nanobodies represents a novel therapeutic approach for treating AD where potentially harmful side effects can be minimized.

AB - Deposition of β-amyloid (Aβ) is considered an important early event in the pathogenesis of Alzheimer's disease (AD), and reduction of Aβ levels in the brain could be a viable therapeutic approach. A potentially noninflammatory route to facilitate clearance and reduce toxicity of Aβ is to degrade the peptide using proteolytic nanobodies. Here we show that a proteolytic nanobody engineered to cleave Aβ at its α-secretase site has potential therapeutic value. The Asec-1A proteolytic nanobody, derived from a parent catalytic light chain antibody, prevents aggregation of monomeric Aβ, inhibits further aggregation of preformed Aβ aggregates, and reduces Aβ-induced cytotoxicity toward a human neuroblastoma cell line. The nanobody also reduces toxicity induced by overexpression of the human amyloid precursor protein (APP) in a Chinese hamster ovary (CHO) cell line by cleaving APP at the α-secretase site which precludes formation of Aβ. Targeted proteolysis of APP and Aβ with catalytic nanobodies represents a novel therapeutic approach for treating AD where potentially harmful side effects can be minimized.

UR - http://www.scopus.com/inward/record.url?scp=77952852954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952852954&partnerID=8YFLogxK

U2 - 10.1021/bi902030m

DO - 10.1021/bi902030m

M3 - Article

C2 - 20429609

AN - SCOPUS:77952852954

VL - 49

SP - 4501

EP - 4508

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 21

ER -